Literature DB >> 12044328

Serum antibodies to oxidized low-density lipoprotein in pregnant women with preeclampsia and chronic hypertension: lack of correlation with lipid peroxides.

E Gratacós1, E Casals, R Deulofeu, O Gómez, V Cararach, P L Alonso, A Fortuny.   

Abstract

OBJECTIVES: To evaluate the circulating levels of antibodies to oxidized low-density lipoprotein (LDL) and their correlation with the lipid peroxide/vitamin E ratio in pregnant women with preeclampsia and chronic hypertension.
METHODS: Antibodies to oxidized LDL were measured by enzyme-linked immunoassay, lipid peroxides (malondialdehyde), and vitamin E were measured by high-pressure liquid chromatography. Patients were 25 healthy pregnant women, 20 previously nonhypertensive women diagnosed with preeclampsia, and 20 women with uncomplicated chronic hypertension.
RESULTS: Serum levels of antibodies to LDL in preeclamptic patients were similar to controls, whereas women with chronic hypertension showed a trend for increased mean levels. Lipid peroxides in serum were significantly increased and vitamin E levels were significantly decreased in preeclampsia with respect to nonhypertensive pregnancy, but no differences were observed for chronic hypertensive women.
CONCLUSIONS: Our results suggest that preeclampsia is not accompanied by increased levels of antibodies to oxidized LDL. By contrast, and according to previous studies in nonpregnant patients, chronic hypertensive patients showed a trend for elevated levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12044328     DOI: 10.1081/PRG-100106967

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  2 in total

1.  What causes endothelial cell activation in preeclamptic women?

Authors:  Scott W Walsh
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

2.  Plasma from preeclamptic women stimulates transendothelial migration of neutrophils.

Authors:  Scott W Walsh
Journal:  Reprod Sci       Date:  2008-12-15       Impact factor: 3.060

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.